Oncimmune Holdings PLC Agreement with pharma company to profile patients (2009M)

TIDMONC

RNS Number : 2009M

Oncimmune Holdings PLC

20 September 2021

20 September 2021

Oncimmune Holdings plc

("Oncimmune" or the "Company")

Agreement signed with leading global pharmaceutical company

to profile patients using ImmunoINSIGHTS service

Oncimmune Holdings plc (AIM: ONC.L), the leading global immunodiagnostics group, today announces it has signed an autoantibody profiling agreement with a leading global pharmaceutical company to evaluate the autoantibody profiles of patient samples in various autoimmune diseases. The initial phase of this project, including the reporting of profiled data, is scheduled to complete by the end of calendar year 2021.

Under this agreement, Oncimmune will utilise its proprietary NavigAID(TM) autoimmune disease characterisation panel to explore the autoantibody profiles of patients with four key autoimmune diseases, namely systemic lupus erythematosus, Sjögren's syndrome, rheumatoid arthritis and sicca syndrome. Oncimmune's customised autoimmune disease panel has been developed to explore the mechanisms of action, disease stratification and response prediction in clinical trials.

The programme is Oncimmune's second agreement with this global partner, and further validates the value of Oncimmune's autoantibody biomarker profiling technology in supporting pharmaceutical and biotechnology companies in their clinical development programmes.

Dr Adam M Hill, CEO of Oncimmune, said: "We are delighted that this global pharmaceutical company has again chosen to partner with Oncimmune, for our world class autoantibody biomarker profiling technology and autoimmune expertise . We are confident that this latest programme will form part of a larger and long-term collaboration and we look forward to supporting their programmes in immunology further through clinical development.

"Today's agreement further demonstrates the strength of our ImmunoINSIGHTS service, the increasing recognition of Oncimmune's expertise in autoimmune disease, and our partnering strategy. This new contract is also a good illustration of the growing uptake of our services, validating our decision to invest in the physical and human infrastructure of our platform to increase capacity significantly, with further pipeline conversion expected over the coming months and beyond."

For further information:

Oncimmune Holdings plc

Dr Adam M Hill, Chief Executive Officer

Matthew Hall, Chief Financial Officer

[e-mail]

Zeus Capital Limited (Nominated Adviser and Joint Broker)

Andrew Jones, Daniel Harris, James Hornigold

[phone]

Singer Capital Markets (Joint Broker)

Aubrey Powell, Harry Gooden, George Tzimas, James Fischer

[phone]

WG Partners (Joint Broker)

David Wilson, Nigel Barnes, Nigel Birks

[phone]

Media enquiries:

FTI Consulting

Ben Atwell, Michael Trace, Alex Davis

[e-mail]

[phone]

About Oncimmune

Oncimmune is a leading immunodiagnostics developer, primarily focused on the growing fields of immuno-oncology, autoimmune disease and infectious diseases. Oncimmune has a diversified and growing revenue both from its portfolio of diagnostic products to detect early-stage cancer and its contract discovery and development service business whose platform delivers actionable insights into therapies to the Company's pharmaceutical and biotech partners .

Our understanding of the immune system enables us to harness its sophisticated response to disease to detect cancer earlier and to support the development of better therapies. The key to improving cancer survival is early detection and better selection for therapy. As a company, we are driven by our passion to improve cancer survival and to give people extra time.

Oncimmune's ImmunoINSIGHTS platform enables life science organisations to optimise drug development and delivery, leading to more effectively targeted and safer treatments for patients. Oncimmune's immunodiagnostic technology, EarlyCDT, can detect and help identify cancer on average four years earlier than standard clinical diagnosis. Our lead diagnostic test, EarlyCDT Lung, targets a vast market estimated to grow to GBP3.8bn by 2024. With over 200,000 tests already performed for patients worldwide and its use being supported by peer reviewed data in over 12,000 patients, we are poised to become an integral component of future lung cancer detection programmes, globally.

Oncimmune's diagnostic products business is located at its laboratory facility in Nottingham, UK and its ImmunoINSIGHTS service business at its discovery research centre in Dortmund, Germany. The ImmunoINSIGHTS business development team are based in the US and Oncimmune is seeking to replicate the Dortmund facility in the US in the medium term.

For more information, visit www.oncimmune.com

What is ImmunoINSIGHTS?

The ImmunoINSIGHTS service business leverages Oncimmune's technology platform and methodologies across multiple diseases, to offer life-science organisations actionable insights for therapies across the development and product lifecycle. Our core immune-profiling technology is underpinned by our library of over eight thousand immunogenic proteins, one of the largest of its kind. This helps identify trial participants and patients into clinically relevant subgroups, enabling development of targeted and more effective treatments.

What is NavigAID?

Oncimmune's NavigAID arrays are thoroughly validated containing well defined antigen panels, largely encompassing markers of interest for each of the disease types being investigated.

Our portfolio of panels includes out-of-the-box NavigAID arrays for immuno-oncology, autoimmune and infectious diseases. These validated panels are frequently used as the starting point for collaborations with partners to add further markers of interest to their specific therapy and its specific indication.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

AGRLRMATMTMBBAB

(END) Dow Jones Newswires

September 20, 2021 02:00 ET (06:00 GMT)